ISBN 10: 1500333514 / ISBN 13: 9781500333515
Usato / Quantità: 0
Copie del libro da altre librerie
Mostra tutte le  copie di questo libro

Libro

Purtroppo questa copia non è più disponibile. Di seguito ti proponiamo una lista di copie simili.

Descrizione:

Brand New, Unread Copy in Perfect Condition. A+ Customer Service!. Codice inventario libreria

Su questo libro:

Book ratings provided by Goodreads):
0 valutazione media
(0 valutazioni)

Riassunto: Alcohol misuse, or unhealthful alcohol use, which includes the full spectrum from drinking above recommended limits (i.e., risky/hazardous drinking) to alcohol dependence, is associated with numerous health and social problems, more than 85,000 deaths per year in the U.S., and an estimated annual cost to society of more than $220 billion. Alcohol misuse is estimated to be the third leading cause of preventable mortality in the U.S., following tobacco use and being overweight. In the past, alcohol-use disorders (AUDs) included harmful use, alcohol abuse, and alcohol dependence. Diagnostic criteria for AUDs have evolved. Prevalence of AUDs is higher for men than for women, with estimates indicating a lifetime risk of more than 20 percent for men. Alcohol dependence has lifetime prevalence rates of about 17 percent for men and 8 percent for women. AUDs cause substantial morbidity and mortality—threefold to fourfold increased rates of early mortality. They are associated with hypertension, heart disease, stroke, cancer, liver cirrhosis, amnesias, cognitive impairment, sleep problems, peripheral neuropathy, gastritis and gastric ulcers, pancreatitis, decreased bone density, anemia, depression, insomnia, anxiety, suicide, and fetal alcohol syndrome. Excessive alcohol consumption is also a major factor in injury and violence. Acute alcohol-related harm can be the result of fires, drowning, falls, homicide, suicide, motor vehicle crashes, child maltreatment, and pedestrian injuries. In addition, AUDs can complicate the assessment and treatment of other medical and psychiatric problems. The use of medications for AUDs is associated with uncertainty and variation across providers and settings. Since the last report, there has been more than a tenfold increase in the number of individuals studied in controlled clinical trials of naltrexone and acamprosate, and many trials of medications that are not FDA approved. Other reasons for conducting a new review on this topic include the following: (1) to assess the comparative effectiveness of the FDA-approved medications; (2) to determine whether any agents that are not FDA approved have evidence supporting their efficacy; (3) to evaluate the evidence on intramuscular naltrexone, a fairly recently approved medication; (4) to evaluate whether trials provide evidence of effectiveness in primary care settings; (5) to assess whether some medications are more or less effective for adults with specific genotypes; and (6) to provide a comprehensive review of medications for AUDs that is relevant for clinicians, researchers, and policymakers. This report focuses on clinically relevant medications—those commonly used, those with sufficient literature for systematic review, and those of greatest interest to clinicians and to the developers of guidelines. The following Key Questions addressed include: KQ 1a: Which medications are efficacious for improving consumption outcomes for adults with AUDs in outpatient settings? KQ 1b: How do medications for adults with AUDs compare for improving consumption outcomes in outpatient settings? KQ 2a: Which medications are efficacious for improving health outcomes for adults with AUDs in outpatient settings? KQ 2b: How do medications for adults with AUDs compare for improving health outcomes in outpatient settings? KQ3a: What adverse effects are associated with medications for adults with AUDs in outpatient settings? KQ 3b: How do medications for adults with AUDs compare for adverse effects in outpatient settings? KQ 4: Are medications for treating adults with AUDs effective in primary care settings? KQ 5: Are any of the medications more or less effective than other medications for men or women, older adults, young adults, racial or ethnic minorities, smokers, or those with co-occurring disorders? KQ 6: Are any of the medications more or less effective for adults with specific genotypes (e.g., related to polymorphisms of the mu-opioid receptor gene [OPRM1])?

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

Dati bibliografici

Condizione libro: New

I migliori risultati di ricerca su AbeBooks

1.

Human Services, U. S. Department of Heal
ISBN 10: 1500333514 ISBN 13: 9781500333515
Nuovi Quantità: > 20
Print on Demand
Da
Books2Anywhere
(Fairford, GLOS, Regno Unito)
Valutazione libreria
[?]

Descrizione libro 2014. PAP. Condizione libro: New. New Book. Delivered from our US warehouse in 10 to 14 business days. THIS BOOK IS PRINTED ON DEMAND.Established seller since 2000. Codice libro della libreria IP-9781500333515

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 22,59
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 10,17
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

2.

Human Services, U. S. Department of Heal
ISBN 10: 1500333514 ISBN 13: 9781500333515
Nuovi Quantità: > 20
Print on Demand
Da
Pbshop
(Wood Dale, IL, U.S.A.)
Valutazione libreria
[?]

Descrizione libro 2014. PAP. Condizione libro: New. New Book.Shipped from US within 10 to 14 business days.THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Codice libro della libreria IP-9781500333515

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 26,67
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 3,46
In U.S.A.
Destinazione, tempi e costi

3.

ISBN 10: 1500333514 ISBN 13: 9781500333515
Nuovi Quantità: > 20
Print on Demand
Da
BWB
(Valley Stream, NY, U.S.A.)
Valutazione libreria
[?]

Descrizione libro Condizione libro: New. This item is Print on Demand - Depending on your location, this item may ship from the US or UK. Codice libro della libreria POD_9781500333515

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 32,69
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
In U.S.A.
Destinazione, tempi e costi

4.

U. S. Department of Health and Human Services
Editore: CreateSpace Independent Publishing Platform
ISBN 10: 1500333514 ISBN 13: 9781500333515
Nuovi Paperback Quantità: 20
Print on Demand
Da
BuySomeBooks
(Las Vegas, NV, U.S.A.)
Valutazione libreria
[?]

Descrizione libro CreateSpace Independent Publishing Platform. Paperback. Condizione libro: New. This item is printed on demand. Paperback. 452 pages. Dimensions: 11.0in. x 8.5in. x 1.0in.Alcohol misuse, or unhealthful alcohol use, which includes the full spectrum from drinking above recommended limits (i. e. , riskyhazardous drinking) to alcohol dependence, is associated with numerous health and social problems, more than 85, 000 deaths per year in the U. S. , and an estimated annual cost to society of more than 220 billion. Alcohol misuse is estimated to be the third leading cause of preventable mortality in the U. S. , following tobacco use and being overweight. In the past, alcohol-use disorders (AUDs) included harmful use, alcohol abuse, and alcohol dependence. Diagnostic criteria for AUDs have evolved. Prevalence of AUDs is higher for men than for women, with estimates indicating a lifetime risk of more than 20 percent for men. Alcohol dependence has lifetime prevalence rates of about 17 percent for men and 8 percent for women. AUDs cause substantial morbidity and mortalitythreefold to fourfold increased rates of early mortality. They are associated with hypertension, heart disease, stroke, cancer, liver cirrhosis, amnesias, cognitive impairment, sleep problems, peripheral neuropathy, gastritis and gastric ulcers, pancreatitis, decreased bone density, anemia, depression, insomnia, anxiety, suicide, and fetal alcohol syndrome. Excessive alcohol consumption is also a major factor in injury and violence. Acute alcohol-related harm can be the result of fires, drowning, falls, homicide, suicide, motor vehicle crashes, child maltreatment, and pedestrian injuries. In addition, AUDs can complicate the assessment and treatment of other medical and psychiatric problems. The use of medications for AUDs is associated with uncertainty and variation across providers and settings. Since the last report, there has been more than a tenfold increase in the number of individuals studied in controlled clinical trials of naltrexone and acamprosate, and many trials of medications that are not FDA approved. Other reasons for conducting a new review on this topic include the following: (1) to assess the comparative effectiveness of the FDA-approved medications; (2) to determine whether any agents that are not FDA approved have evidence supporting their efficacy; (3) to evaluate the evidence on intramuscular naltrexone, a fairly recently approved medication; (4) to evaluate whether trials provide evidence of effectiveness in primary care settings; (5) to assess whether some medications are more or less effective for adults with specific genotypes; and (6) to provide a comprehensive review of medications for AUDs that is relevant for clinicians, researchers, and policymakers. This report focuses on clinically relevant medicationsthose commonly used, those with sufficient literature for systematic review, and those of greatest interest to clinicians and to the developers of guidelines. The following Key Questions addressed include: KQ 1a: Which medications are efficacious for improving consumption outcomes for adults with AUDs in outpatient settings KQ 1b: How do medications for adults with AUDs compare for improving consumption outcomes in outpatient settings KQ 2a: Which medications are efficacious for improving health outcomes for adults with AUDs in outpatient settings KQ 2b: How do medications for adults with AUDs compare for improving health outcomes in outpatient settings KQ3a: What adverse effects are associated with medications for adults with AUDs in outpatient settings KQ 3b: How do medications for adults with AUDs compare for adverse effects in outpatient settings KQ 4: Are medications for treating adults with AUDs effective in primary care settings KQ 5: Are any of the medications more or less effective than other medications for men or women, older adults, young adults, racial or ethnic minorities, smokers, or those with co-occurring disorders KQ 6: Are any of the medications more or less This item ships from La Vergne,TN. Paperback. Codice libro della libreria 9781500333515

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 41,96
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 3,43
In U.S.A.
Destinazione, tempi e costi

5.

U S Department of Healt Human Services, Agency for Healthcare Resea And Quality
Editore: Createspace, United States (2014)
ISBN 10: 1500333514 ISBN 13: 9781500333515
Nuovi Paperback Quantità: 10
Print on Demand
Da
The Book Depository
(London, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Createspace, United States, 2014. Paperback. Condizione libro: New. Language: English . Brand New Book ***** Print on Demand *****.Alcohol misuse, or unhealthful alcohol use, which includes the full spectrum from drinking above recommended limits (i.e., risky/hazardous drinking) to alcohol dependence, is associated with numerous health and social problems, more than 85,000 deaths per year in the U.S., and an estimated annual cost to society of more than $220 billion. Alcohol misuse is estimated to be the third leading cause of preventable mortality in the U.S., following tobacco use and being overweight. In the past, alcohol-use disorders (AUDs) included harmful use, alcohol abuse, and alcohol dependence. Diagnostic criteria for AUDs have evolved. Prevalence of AUDs is higher for men than for women, with estimates indicating a lifetime risk of more than 20 percent for men. Alcohol dependence has lifetime prevalence rates of about 17 percent for men and 8 percent for women. AUDs cause substantial morbidity and mortality-threefold to fourfold increased rates of early mortality. They are associated with hypertension, heart disease, stroke, cancer, liver cirrhosis, amnesias, cognitive impairment, sleep problems, peripheral neuropathy, gastritis and gastric ulcers, pancreatitis, decreased bone density, anemia, depression, insomnia, anxiety, suicide, and fetal alcohol syndrome. Excessive alcohol consumption is also a major factor in injury and violence. Acute alcohol-related harm can be the result of fires, drowning, falls, homicide, suicide, motor vehicle crashes, child maltreatment, and pedestrian injuries. In addition, AUDs can complicate the assessment and treatment of other medical and psychiatric problems. The use of medications for AUDs is associated with uncertainty and variation across providers and settings. Since the last report, there has been more than a tenfold increase in the number of individuals studied in controlled clinical trials of naltrexone and acamprosate, and many trials of medications that are not FDA approved. Other reasons for conducting a new review on this topic include the following: (1) to assess the comparative effectiveness of the FDA-approved medications; (2) to determine whether any agents that are not FDA approved have evidence supporting their efficacy; (3) to evaluate the evidence on intramuscular naltrexone, a fairly recently approved medication; (4) to evaluate whether trials provide evidence of effectiveness in primary care settings; (5) to assess whether some medications are more or less effective for adults with specific genotypes; and (6) to provide a comprehensive review of medications for AUDs that is relevant for clinicians, researchers, and policymakers. This report focuses on clinically relevant medications-those commonly used, those with sufficient literature for systematic review, and those of greatest interest to clinicians and to the developers of guidelines. The following Key Questions addressed include: KQ 1a: Which medications are efficacious for improving consumption outcomes for adults with AUDs in outpatient settings? KQ 1b: How do medications for adults with AUDs compare for improving consumption outcomes in outpatient settings? KQ 2a: Which medications are efficacious for improving health outcomes for adults with AUDs in outpatient settings? KQ 2b: How do medications for adults with AUDs compare for improving health outcomes in outpatient settings? KQ3a: What adverse effects are associated with medications for adults with AUDs in outpatient settings? KQ 3b: How do medications for adults with AUDs compare for adverse effects in outpatient settings? KQ 4: Are medications for treating adults with AUDs effective in primary care settings? KQ 5: Are any of the medications more or less effective than other medications for men or women, older adults, young adults, racial or ethnic minorities, smokers, or those with co-occurring disorders? KQ 6: Are any of the medications more or less effective for adults with specific genotypes (e.g., related to. Codice libro della libreria APC9781500333515

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 56,45
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

6.

U S Department of Healt Human Services, Agency for Healthcare Resea And Quality
Editore: Createspace, United States (2014)
ISBN 10: 1500333514 ISBN 13: 9781500333515
Nuovi Paperback Quantità: 10
Print on Demand
Da
The Book Depository US
(London, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Createspace, United States, 2014. Paperback. Condizione libro: New. Language: English . Brand New Book ***** Print on Demand *****. Alcohol misuse, or unhealthful alcohol use, which includes the full spectrum from drinking above recommended limits (i.e., risky/hazardous drinking) to alcohol dependence, is associated with numerous health and social problems, more than 85,000 deaths per year in the U.S., and an estimated annual cost to society of more than $220 billion. Alcohol misuse is estimated to be the third leading cause of preventable mortality in the U.S., following tobacco use and being overweight. In the past, alcohol-use disorders (AUDs) included harmful use, alcohol abuse, and alcohol dependence. Diagnostic criteria for AUDs have evolved. Prevalence of AUDs is higher for men than for women, with estimates indicating a lifetime risk of more than 20 percent for men. Alcohol dependence has lifetime prevalence rates of about 17 percent for men and 8 percent for women. AUDs cause substantial morbidity and mortality-threefold to fourfold increased rates of early mortality. They are associated with hypertension, heart disease, stroke, cancer, liver cirrhosis, amnesias, cognitive impairment, sleep problems, peripheral neuropathy, gastritis and gastric ulcers, pancreatitis, decreased bone density, anemia, depression, insomnia, anxiety, suicide, and fetal alcohol syndrome. Excessive alcohol consumption is also a major factor in injury and violence. Acute alcohol-related harm can be the result of fires, drowning, falls, homicide, suicide, motor vehicle crashes, child maltreatment, and pedestrian injuries. In addition, AUDs can complicate the assessment and treatment of other medical and psychiatric problems. The use of medications for AUDs is associated with uncertainty and variation across providers and settings. Since the last report, there has been more than a tenfold increase in the number of individuals studied in controlled clinical trials of naltrexone and acamprosate, and many trials of medications that are not FDA approved. Other reasons for conducting a new review on this topic include the following: (1) to assess the comparative effectiveness of the FDA-approved medications; (2) to determine whether any agents that are not FDA approved have evidence supporting their efficacy; (3) to evaluate the evidence on intramuscular naltrexone, a fairly recently approved medication; (4) to evaluate whether trials provide evidence of effectiveness in primary care settings; (5) to assess whether some medications are more or less effective for adults with specific genotypes; and (6) to provide a comprehensive review of medications for AUDs that is relevant for clinicians, researchers, and policymakers. This report focuses on clinically relevant medications-those commonly used, those with sufficient literature for systematic review, and those of greatest interest to clinicians and to the developers of guidelines. The following Key Questions addressed include: KQ 1a: Which medications are efficacious for improving consumption outcomes for adults with AUDs in outpatient settings? KQ 1b: How do medications for adults with AUDs compare for improving consumption outcomes in outpatient settings? KQ 2a: Which medications are efficacious for improving health outcomes for adults with AUDs in outpatient settings? KQ 2b: How do medications for adults with AUDs compare for improving health outcomes in outpatient settings? KQ3a: What adverse effects are associated with medications for adults with AUDs in outpatient settings? KQ 3b: How do medications for adults with AUDs compare for adverse effects in outpatient settings? KQ 4: Are medications for treating adults with AUDs effective in primary care settings? KQ 5: Are any of the medications more or less effective than other medications for men or women, older adults, young adults, racial or ethnic minorities, smokers, or those with co-occurring disorders? KQ 6: Are any of the medications more or less effective for adults with specific genotypes (e.g., related to. Codice libro della libreria APC9781500333515

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 56,64
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

7.

Agency for and Quality and U. S. Department Human
ISBN 10: 1500333514 ISBN 13: 9781500333515
Nuovi Quantità: 1
Da
Castle Rock
(Pittsford, NY, U.S.A.)
Valutazione libreria
[?]

Descrizione libro Condizione libro: Brand New. Book Condition: Brand New. Codice libro della libreria 97815003335151.0

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 57,76
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 3,46
In U.S.A.
Destinazione, tempi e costi